Forest Whitaker, Ajay Banga, Juanes, Tokata Iron Eyes, Brandon Stanton, Dr. Lisa Su and Nicholas Donofrio to Receive the International Peace Honors Presented by PeaceTech Lab
24.12.2021 13:00:00 EET | Business Wire | Press release
The International Peace Honors (IPH), created by PeaceTech Lab, an award-winning non-profit organization founded by the United States Institute of Peace, will recognize Forest Whitaker, Ajay Banga, Juanes, Tokata Iron Eyes, Brandon Stanton, Dr. Lisa Su and Nicholas Donofrio for being global change-makers who have positively impacted the world through targeted activism. The virtual event airs Sunday, February 27th, 2022, at 8:00 pm EST. To register to watch visit: internationalpeacehonors.org.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005439/en/
The 2022 International Peace Honorees. (Photo: Business Wire)
“This year’s International Peace Honorees inspire us to greater hope and urgency, by showing what can happen when we leverage technology and media in their highest forms. From promoting peace and non-violence through music, to helping people improve their lives through the digital economy, protect the planet, and raise up a generation of new voices, their tireless work for the betterment of humanity is to be lauded. We are thrilled to recognize each of these outstanding social leaders,” said Sheldon Himelfarb, President & CEO, PeaceTech Lab.
Academy Award Winner, Forest Whitaker will receive the recognition for his everlasting commitment to empowering youth and promoting peace globally. Whitaker is the CEO/Founder of the Whitaker Peace & Development Initiative (WPDI), which provides educational tools and economic opportunities to young people in places touched by exclusion, violence and armed conflict.
Mastercard Executive Chairman, Ajay Banga will receive the honor for his outstanding contributions in bringing the digital economy to over 1 billion people, thus creating a sustainable economy through technology.
Renowned Singer-Songwriter and Social Advocate, Juanes will be honored for his dedication to youth empowerment and peace in his native Colombia through his Mi Sangre Foundation, a peace-building non-profit organization he co-founded alongside Catalina Cock Duque.
Youth Activist, Tokata Iron Eyes is set to be honored for her impassioned advocacy for Indigenous rights and the global climate movement. At age 18, she becomes the youngest person to receive the prestigious award.
Brandon Stanton, the creator of “Humans of New York”, will be celebrated for his dedication to fostering empathy and interconnectedness through powerful storytelling.
AMD ’s President and CEO, Dr. Lisa Su, will be recognized for revolutionizing high performance computing, donating supercomputing power for public good efforts focused on infectious disease research, and for inspiring people from all backgrounds to pursue careers in science and technology.
Lastly, former IBM EVP of Innovation and Technology Nicholas Donofrio, will receive the honor for his contributions to the international community of women and underrepresented youth in the fields of education, engineering, business and mathematics.
“The exceptionalism of our honorees reminds us that we’re all capable of rising to the challenges that negatively affect our world. I’m proud to extol their valuable social contributions and celebrate their vast achievements,” added MariaEsmeralda Paguaga, executive producer of the International Peace Honors .
The host, performers, and special guests will be announced in the upcoming weeks.
The International Peace Honors are made possible with the generosity of its sponsors and donors: Mastercard, BNY Mellon, The MITRE Corporation, Microsoft, Pitney Bowes, Liberty Mutual Insurance, Ernst & Young, Mercator XXI, KUDO, Wipro, and Alliance for Peacebuilding.
Follow @internationalpeacehonors for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005439/en/
Contact information
Press: Janice Torres,
janice@peacetechlab.org
For Talent & Publicity: Laura Mejia Cruz,
laura@dtapr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom